全文获取类型
收费全文 | 950篇 |
免费 | 86篇 |
国内免费 | 64篇 |
专业分类
耳鼻咽喉 | 3篇 |
儿科学 | 5篇 |
妇产科学 | 4篇 |
基础医学 | 32篇 |
口腔科学 | 39篇 |
临床医学 | 110篇 |
内科学 | 164篇 |
皮肤病学 | 9篇 |
神经病学 | 15篇 |
特种医学 | 12篇 |
外科学 | 38篇 |
综合类 | 228篇 |
预防医学 | 17篇 |
眼科学 | 7篇 |
药学 | 353篇 |
2篇 | |
中国医学 | 45篇 |
肿瘤学 | 17篇 |
出版年
2023年 | 8篇 |
2022年 | 3篇 |
2021年 | 15篇 |
2020年 | 17篇 |
2019年 | 16篇 |
2018年 | 18篇 |
2017年 | 35篇 |
2016年 | 35篇 |
2015年 | 27篇 |
2014年 | 62篇 |
2013年 | 76篇 |
2012年 | 75篇 |
2011年 | 88篇 |
2010年 | 66篇 |
2009年 | 82篇 |
2008年 | 68篇 |
2007年 | 69篇 |
2006年 | 68篇 |
2005年 | 58篇 |
2004年 | 47篇 |
2003年 | 27篇 |
2002年 | 18篇 |
2001年 | 28篇 |
2000年 | 17篇 |
1999年 | 14篇 |
1998年 | 12篇 |
1997年 | 12篇 |
1996年 | 4篇 |
1995年 | 5篇 |
1994年 | 6篇 |
1993年 | 6篇 |
1992年 | 2篇 |
1991年 | 4篇 |
1990年 | 4篇 |
1989年 | 6篇 |
1988年 | 2篇 |
排序方式: 共有1100条查询结果,搜索用时 31 毫秒
51.
目的 观察青鹏胶囊对流行性感冒病毒的抑制作用。方法应用细胞培养技术,在传代细胞上进行青鹏胶囊抗流感甲,和乙型病毒的抑制试验。结果该药对甲,型病毒有明显的中和、治疗作用,对乙型病毒中和、治疗作用不明显。结论 青鹏胶囊对流行性感冒病毒-甲,型具有明显的抑制作用。 相似文献
52.
辛伐他汀对脐静脉内皮细胞金属基质蛋白酶9表达的影响 总被引:2,自引:2,他引:0
目的观察辛伐他汀对脐静脉内皮细胞(human umbilical vein endothelial cell,HUVEC)金属基质蛋白酶9(matrix metalloproteinase-9,MMP-9)表达的影响。方法采用逆转录聚合酶链反应及蛋白质免疫印迹分析检测MMP-9mRNA转录和蛋白水平表达,观察辛伐他汀不同浓度及不同孵育时间HUVECMMP-9表达的影响。结果辛伐他汀呈浓度和时间依赖性减低HU-VEC的MMP-9mRNA转录和蛋白水平的表达。结论辛伐他汀可抑制HUVE CMMP-9表达,防治动脉粥样硬化。 相似文献
53.
辛伐他汀干预急性心肌梗死后心肌营养素-1的表达与左室重塑的关系 总被引:1,自引:0,他引:1
目的研究辛伐他汀干预急性心肌梗死(AMI)后左室非梗死区(LVNIZ)心肌营养素-1(CT-1)表达及左室重塑(LVRM)的进程。方法♂SD大鼠分为4组,AMI组、AMI+辛伐他汀组、假手术组和正常组,每组8只。前2组大鼠结扎左冠状动脉前降支(LAD)制备成AMI模型。AMI+辛伐他汀组在手术后d2予辛伐他汀40mg.kg-1.d-1灌胃。余3组给予生理盐水灌胃。4wk后测定左室重量指数,LVNIZ心肌细胞横截面积,LVNIZ心肌胶原容积分数变化,用RT-PCR和Western blot法测定LVNIZ CT-1mRNA表达和蛋白合成水平。结果与正常和假手术组比较,AMI组LVRM参数:左室重量指数(LVWI),心肌细胞横截面积(CA),Ⅰ、Ⅲ胶原容积分数(CVFⅠ、CVFⅢ),均明显增加(P<0.05),LVNIZ CT-1mRNA表达和蛋白合成水平于4wk后明显增加(P<0.05)。与AMI组相比,AMI+辛伐他汀组LVRM明显减轻,LVNIZ CT-1mRNA表达和蛋白合成水平明显下调(P<0.05)。结论大鼠AMI后LVNIZ CT-1mR-NA和蛋白的过度表达与AMI后LVRM的发生有联系,辛伐他汀可改善LVRM,其机制可能与抑制CT-1基因过度表达与蛋白合成有关。 相似文献
54.
不同剂量辛伐他汀治疗急性心肌梗死疗效观察 总被引:1,自引:0,他引:1
目的观察辛伐他汀对急性心肌梗死早期溶栓治疗的临床疗效。方法64例急性心肌梗死(AMI)患者随机分2组,常规剂量组(A组,n=32),较高剂量组(B组,n=32),其中常规剂量组在发病后给予辛伐他汀20mg·次^-1,1次·d^-1,较高剂量组给予辛伐他汀40mg·次^-1,1次·d^-1,持续6个月,溶栓及其他常规治疗相同。治疗前及治疗2周后测量心功能、血清高敏C反应蛋白(hs—CRP)、血脂及肝功能等指标。结果治疗2周后,2组心功能均得到改善,B组优于A组,差异有显著性(P〈0.05)。2组hs—CRP与治疗前相比均有显著下降(P〈0.05),B组hs—CRP下降更明显(P〈0.01);2组LDL-C和TC均有下降,B组显著低于常规治疗组(P〈0.05)。结论急性心肌梗死患者早期给予辛伐他汀治疗,短期就有抗炎作用,且抗炎作用独立于调脂作用,较高剂量的辛伐他汀治疗可能获益更大。 相似文献
55.
Gerald H Tomkin 《British journal of pharmacology》2009,156(8):1216-1217
Ezetimibe, a Niemann Pick C1-like1 inhibitor, inhibits cholesterol absorption. The drug has been shown to affect lipid raft function in monocytes and therefore may inhibit lipid accumulation in the atheromatous plaque with a mechanism that is unrelated to its effect in reducing cholesterol absorption. In this issue of the British journal of pharmacology, Gómez-Garre et al. demonstrate that ezetimibe and simvastatin both have a beneficial effect on the atheromatous plaque, which may be due to their effect on both monocyte/macrophage function and reduction in nuclear factor-κB activity. Whether these results in a rabbit model of atherosclerosis can be translated into human atherosclerosis awaits further studies. 相似文献
56.
Joseph Pagkalos Jae Min Cha Yunyi Kang Manolis Heliotis Eleftherios Tsiridis Athanasios Mantalaris 《Journal of bone and mineral research》2010,25(11):2470-2478
Statins are potent inhibitors of cholesterol synthesis. Several statins are available with different molecular and pharmacokinetic properties. Simvastatin is more lipophilic than pravastatin and has a higher affinity to phospholipid membranes than atorvastatin, allowing its passive diffusion through the cell membrane. In vitro studies on bone marrow stromal cells, osteoblast‐like cells, and embryonic stem cells have shown statins to have cholesterol‐independent anabolic effects on bone metabolism; alas, statins were supplemented in osteogenic medium, which does not facilitate elucidation of their potential osteoinductive properties. Embryonic stem cells (ESCs), derived from the inner cell mass of the blastocyst, are unique in that they enjoy perpetual self‐proliferation, are pluripotent, and are able to differentiate toward all the cellular lineages composing the body, including the osteogenic lineage. Consequently, ESCs represent a potentially potent cell source for future clinical cellular therapies of various bone diseases, even though there are several hurdles that still need to be overcome. Herein we demonstrate, for the first time to our knowledge, that simvastatin induces murine ESC (mESC) differentiation toward the osteogenic lineage in the absence of osteoinductive supplements. Specifically, we found that a simvastatin concentration in the micromolar range and higher was toxic to the cells and that an effective concentration for osteoinduction is 0.1 nM, as shown by increased alizarin red staining as well as increased osteocalcin and osetrix gene expression. These results suggest that in the future, lipophilic simvastatin may provide a novel pharmacologic agent for bone tissue engineering applications. © 2010 American Society for Bone and Mineral Research. 相似文献
57.
58.
Li-Jun Deng Yan-Lin Wu Xian-Hua He Ke-Nan Xie 《Journal of biomaterials science. Polymer edition》2013,24(18):2237-2251
AbstractA strategy developed for obtaining positive cellular responses remains to be focused in the filed of functional biomimetics. In this study, a hydrogel covered simvastatin-loaded polyetheretherketone (PEEK) bio-composites was constructed with the purpose of bone tissue regeneration therapy. Briefly, a three-dimensional (3D) porous structure was fabricated on PEEK surface; then the substrate was functionalized with the poly(L-lactic acid)/simvastatin porous film and hyaluronic acid hydrogel subsequently. In vitro cell attachment, proliferation, and cytoskeletal observation experiments reveal that our scaffolds show better bio-affinity due to the layer of hyaluronic acid hydrogel compared with control. Furthermore, the alkaline phosphatase activity, calcium mineral deposition evaluation, and gene expression for osteogenic potential all exhibit that the superior osteogenic differentiation of MC3T3-E1 pre-osteoblasts on our scaffolds. Therefore, our PEEK samples loaded with simvastatin and covered with hyaluronic acid hydrogel hold great potential in clinical applications for bone repair. 相似文献
59.
60.
目的研究辛伐他汀对慢性阻塞性肺病大鼠基质金属蛋白酶-9(MMP-9)及其抑制剂(TIMP-1)表达的影响。方法选用30只健康的雄性SD大鼠作为实验材料,将30只大鼠分为三组:A组10只,B组10只,C组10只。B组和C组构建慢阻肺模型,C组大鼠采用辛伐他汀治疗。比较各组大鼠的一般症状、肺功能、支气管肺泡灌洗液(BALF)细胞计数和血清MMP-9、TIMP-1水平。结果 4w后,各组大鼠的体质量、FEV0.3s、FVC、FEV0.3s/FVC、PEV和BALF细胞计数具有统计学差异(P0.05)。A组大鼠MMP-9为(87.14±21.76)ng/ml,TIMP-1为(82.16±14.89)ng/ml,MMP-9/TIMP-1为(1.07±0.09);B组大鼠MMP-9为(241.58±38.94)ng/ml,TIMP-1为(167.92±19.76)ng/ml,MMP-9/TIMP-1为(1.44±0.21);C组大鼠MMP-9为(134.25±29.15)ng/ml,TIMP-1为(119.41±15.62)ng/ml,MMP-9/TIMP-1为(1.12±0.1),差异具有统计学意义(P0.05)。结论辛伐他汀可以降低慢阻肺大鼠基质金属蛋白酶-9及其抑制剂的表达水平,并改善两者的比例失衡。 相似文献